Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
88% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. MDXG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MDXG' s 10-Year Cash to Debt Range
Min: 0  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.81
MDXG's Equity to Asset is ranked higher than
75% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. MDXG: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
MDXG' s 10-Year Equity to Asset Range
Min: 0.44  Med: 0.82 Max: 0.89
Current: 0.81
0.44
0.89
Interest Coverage No Debt
MDXG's Interest Coverage is ranked higher than
81% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. MDXG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MDXG' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 6
Z-Score: 37.07
M-Score: -2.43
WACC vs ROIC
2.28%
31.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 8.78
MDXG's Operating margin (%) is ranked higher than
67% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. MDXG: 8.78 )
Ranked among companies with meaningful Operating margin (%) only.
MDXG' s 10-Year Operating margin (%) Range
Min: -1334.98  Med: -19.79 Max: 6.01
Current: 8.78
-1334.98
6.01
Net-margin (%) 8.05
MDXG's Net-margin (%) is ranked higher than
72% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. MDXG: 8.05 )
Ranked among companies with meaningful Net-margin (%) only.
MDXG' s 10-Year Net-margin (%) Range
Min: -1447.4  Med: -28.32 Max: 5.26
Current: 8.05
-1447.4
5.26
ROE (%) 13.77
MDXG's ROE (%) is ranked higher than
80% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. MDXG: 13.77 )
Ranked among companies with meaningful ROE (%) only.
MDXG' s 10-Year ROE (%) Range
Min: -276.61  Med: -113.28 Max: 7.64
Current: 13.77
-276.61
7.64
ROA (%) 11.55
MDXG's ROA (%) is ranked higher than
88% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: -0.33 vs. MDXG: 11.55 )
Ranked among companies with meaningful ROA (%) only.
MDXG' s 10-Year ROA (%) Range
Min: -557.14  Med: -81.88 Max: 6.41
Current: 11.55
-557.14
6.41
ROC (Joel Greenblatt) (%) 56.67
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. MDXG: 56.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDXG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2458.54  Med: -847.17 Max: 39.25
Current: 56.67
-2458.54
39.25
Revenue Growth (3Y)(%) 111.50
MDXG's Revenue Growth (3Y)(%) is ranked higher than
99% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. MDXG: 111.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDXG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 293.6
Current: 111.5
0
293.6
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MDXG Guru Trades in Q2 2014

Jim Simons 179,900 sh (New)
Steven Cohen 906,800 sh (unchged)
» More
Q3 2014

MDXG Guru Trades in Q3 2014

Joel Greenblatt 17,878 sh (New)
Jim Simons 251,000 sh (+39.52%)
Steven Cohen 825,000 sh (-9.02%)
» More
Q4 2014

MDXG Guru Trades in Q4 2014

Paul Tudor Jones 19,098 sh (New)
Joel Greenblatt 36,045 sh (+101.62%)
Steven Cohen Sold Out
Jim Simons 198,172 sh (-21.05%)
» More
Q1 2015

MDXG Guru Trades in Q1 2015

Steven Cohen 942,500 sh (New)
Paul Tudor Jones 38,800 sh (+103.16%)
Joel Greenblatt 61,414 sh (+70.38%)
Jim Simons 174,400 sh (-12.00%)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 104.20
MDXG's P/E(ttm) is ranked lower than
90% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 29.20 vs. MDXG: 104.20 )
Ranked among companies with meaningful P/E(ttm) only.
MDXG' s 10-Year P/E(ttm) Range
Min: 89.61  Med: 159.15 Max: 1843.33
Current: 104.2
89.61
1843.33
Forward P/E 40.16
MDXG's Forward P/E is ranked lower than
78% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. MDXG: 40.16 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 107.30
MDXG's PE(NRI) is ranked lower than
92% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 29.20 vs. MDXG: 107.30 )
Ranked among companies with meaningful PE(NRI) only.
MDXG' s 10-Year PE(NRI) Range
Min: 92.3  Med: 168.70 Max: 1106
Current: 107.3
92.3
1106
P/B 13.41
MDXG's P/B is ranked lower than
95% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. MDXG: 13.41 )
Ranked among companies with meaningful P/B only.
MDXG' s 10-Year P/B Range
Min: 5.5  Med: 11.11 Max: 21.82
Current: 13.41
5.5
21.82
P/S 8.65
MDXG's P/S is ranked lower than
80% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. MDXG: 8.65 )
Ranked among companies with meaningful P/S only.
MDXG' s 10-Year P/S Range
Min: 6.84  Med: 11.72 Max: 148
Current: 8.65
6.84
148
PFCF 71.53
MDXG's PFCF is ranked lower than
82% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 31.27 vs. MDXG: 71.53 )
Ranked among companies with meaningful PFCF only.
MDXG' s 10-Year PFCF Range
Min: 61.53  Med: 79.05 Max: 221.2
Current: 71.53
61.53
221.2
POCF 53.65
MDXG's POCF is ranked lower than
81% of the 149 Companies
in the Global Medical Devices industry.

( Industry Median: 22.43 vs. MDXG: 53.65 )
Ranked among companies with meaningful POCF only.
MDXG' s 10-Year POCF Range
Min: 46.15  Med: 73.93 Max: 372
Current: 53.65
46.15
372
EV-to-EBIT 91.59
MDXG's EV-to-EBIT is ranked lower than
92% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 22.74 vs. MDXG: 91.59 )
Ranked among companies with meaningful EV-to-EBIT only.
MDXG' s 10-Year EV-to-EBIT Range
Min: -299.1  Med: -9.50 Max: 1158.8
Current: 91.59
-299.1
1158.8
Current Ratio 4.46
MDXG's Current Ratio is ranked higher than
70% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. MDXG: 4.46 )
Ranked among companies with meaningful Current Ratio only.
MDXG' s 10-Year Current Ratio Range
Min: 0.05  Med: 1.53 Max: 7.08
Current: 4.46
0.05
7.08
Quick Ratio 4.23
MDXG's Quick Ratio is ranked higher than
75% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. MDXG: 4.23 )
Ranked among companies with meaningful Quick Ratio only.
MDXG' s 10-Year Quick Ratio Range
Min: 0.05  Med: 1.51 Max: 6.7
Current: 4.23
0.05
6.7
Days Inventory 108.19
MDXG's Days Inventory is ranked higher than
61% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 130.93 vs. MDXG: 108.19 )
Ranked among companies with meaningful Days Inventory only.
MDXG' s 10-Year Days Inventory Range
Min: 11.88  Med: 129.89 Max: 135.08
Current: 108.19
11.88
135.08
Days Sales Outstanding 81.15
MDXG's Days Sales Outstanding is ranked lower than
61% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. MDXG: 81.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDXG' s 10-Year Days Sales Outstanding Range
Min: 74.94  Med: 88.99 Max: 103.26
Current: 81.15
74.94
103.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 46.65
MDXG's Price/Net Cash is ranked lower than
84% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 14.32 vs. MDXG: 46.65 )
Ranked among companies with meaningful Price/Net Cash only.
MDXG' s 10-Year Price/Net Cash Range
Min: 20.43  Med: 38.43 Max: 140
Current: 46.65
20.43
140
Price/Net Current Asset Value 18.50
MDXG's Price/Net Current Asset Value is ranked lower than
84% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 6.26 vs. MDXG: 18.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDXG' s 10-Year Price/Net Current Asset Value Range
Min: 11.35  Med: 33.93 Max: 147.5
Current: 18.5
11.35
147.5
Price/Tangible Book 16.26
MDXG's Price/Tangible Book is ranked lower than
88% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. MDXG: 16.26 )
Ranked among companies with meaningful Price/Tangible Book only.
MDXG' s 10-Year Price/Tangible Book Range
Min: 10.57  Med: 32.47 Max: 237.5
Current: 16.26
10.57
237.5
Price/Projected FCF 24.39
MDXG's Price/Projected FCF is ranked lower than
94% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. MDXG: 24.39 )
Ranked among companies with meaningful Price/Projected FCF only.
MDXG' s 10-Year Price/Projected FCF Range
Min: 23.64  Med: 30.62 Max: 354.5
Current: 24.39
23.64
354.5
Price/Median PS Value 0.74
MDXG's Price/Median PS Value is ranked higher than
79% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 1.11 vs. MDXG: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
MDXG' s 10-Year Price/Median PS Value Range
Min: 0.62  Med: 1.03 Max: 11.25
Current: 0.74
0.62
11.25
Price/Graham Number 8.66
MDXG's Price/Graham Number is ranked lower than
89% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 2.37 vs. MDXG: 8.66 )
Ranked among companies with meaningful Price/Graham Number only.
MDXG' s 10-Year Price/Graham Number Range
Min: 8.39  Med: 12.14 Max: 20.37
Current: 8.66
8.39
20.37
Earnings Yield (Greenblatt) (%) 1.10
MDXG's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. MDXG: 1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDXG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 0.75 Max: 1.2
Current: 1.1
0.1
1.2

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany,
MiMedx Group Inc was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
Edited Transcript of MDXG earnings conference call or presentation 30-Jul-15 2:30pm GMT Jul 31 2015
MIMEDX GROUP INC Earnings Call scheduled for 10:30 am ET today Jul 30 2015
MiMedx beats 2Q profit forecasts Jul 30 2015
MiMedx beats 2Q profit forecasts Jul 30 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 30 2015
MiMedx Announces Record Results for Second Quarter of 2015 Jul 30 2015
MiMedx Announces Record Results for Second Quarter of 2015 Jul 30 2015
Q2 2015 MiMedx Group Inc Earnings Release - Before Market Open Jul 30 2015
MiMedx Group downgraded by Needham Jul 29 2015
Scientific Study Demonstrates That MiMedx Allografts Stimulate Cellular Proliferation And Migration... Jul 15 2015
Six stocks to watch Jul 15 2015
MiMedx (MDXG) Worth a Look: Stock Adds 5.3% in Session - Tale of the Tape Jul 15 2015
MiMedx Announces Release Date for 2015 Second Quarter Results Jul 08 2015
MiMedx Announces Release Date for 2015 Second Quarter Results Jul 08 2015
EY Entrepreneur Of The Year Program Recognizes Pete Petit, The Chairman & CEO of MiMedx Jun 29 2015
Edited Transcript of MDXG presentation 3-Jun-15 12:30pm GMT Jun 27 2015
The Priceline Group Set to Join the S&P 100; Baxalta to Join the 500; Other Changes to S&P MidCap... Jun 19 2015
$180 million discovery from the placenta Jun 17 2015
MiMedx To Present At The Jefferies 2015 Global Healthcare Conference May 27 2015
MiMedx To Present At The 12th Annual Craig-Hallum Institutional Investor Conference May 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK